Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 49,729 shares of the medical research company’s stock, valued at approximately $763,000. Los Angeles Capital Management & Equity Research Inc. owned about 0.06% of NeoGenomics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of NEO. PNC Financial Services Group Inc. bought a new position in shares of NeoGenomics during the second quarter valued at approximately $272,000. Hussman Strategic Advisors Inc. grew its stake in shares of NeoGenomics by 33.3% during the third quarter. Hussman Strategic Advisors Inc. now owns 200,000 shares of the medical research company’s stock valued at $3,070,000 after buying an additional 50,000 shares during the last quarter. BlackRock Inc. grew its stake in shares of NeoGenomics by 4.7% during the second quarter. BlackRock Inc. now owns 4,149,329 shares of the medical research company’s stock valued at $54,397,000 after buying an additional 184,386 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in shares of NeoGenomics by 0.7% during the second quarter. Artisan Partners Limited Partnership now owns 2,175,072 shares of the medical research company’s stock valued at $28,515,000 after buying an additional 14,583 shares during the last quarter. Finally, Emerald Advisers Inc. PA grew its stake in shares of NeoGenomics by 21.6% during the third quarter. Emerald Advisers Inc. PA now owns 1,671,830 shares of the medical research company’s stock valued at $25,663,000 after buying an additional 297,384 shares during the last quarter. 80.28% of the stock is currently owned by institutional investors.
Shares of NEO stock opened at $15.99 on Friday. The firm has a market cap of $1.49 billion, a PE ratio of 123.00 and a beta of -0.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.98 and a current ratio of 4.13. NeoGenomics, Inc. has a 12-month low of $7.08 and a 12-month high of $19.04.
In related news, insider Steven C. Jones sold 141,127 shares of the company’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $16.66, for a total value of $2,351,175.82. Following the transaction, the insider now directly owns 241,815 shares of the company’s stock, valued at approximately $4,028,637.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kevin C. Johnson sold 66,007 shares of the company’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $17.03, for a total value of $1,124,099.21. Following the completion of the transaction, the director now directly owns 97,873 shares in the company, valued at $1,666,777.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,994,643 shares of company stock worth $83,771,998. Insiders own 12.20% of the company’s stock.
NEO has been the topic of a number of analyst reports. BidaskClub cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 10th. Leerink Swann initiated coverage on NeoGenomics in a report on Tuesday, August 21st. They issued an “outperform” rating and a $18.00 price target for the company. First Analysis set a $16.00 price target on NeoGenomics and gave the company a “buy” rating in a report on Tuesday, September 18th. Craig Hallum boosted their price target on NeoGenomics from $17.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Finally, Raymond James boosted their price target on NeoGenomics from $16.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. NeoGenomics has a consensus rating of “Buy” and a consensus price target of $20.08.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Further Reading: Investing strategies using the yield curve
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.